Antimicrobial resistance surveillance relies larly on analyzing bacterial isolates submitted to the laboratory. This is driven by the efforts of the World Health Organization through its surveillance system GLASS. Given the absence of clinical information, and the high-risk of bias in submitting these specimens, the data do not provide an adequate picture on the prevalence of AMR in given settings. There is an urgent need to supplement this surveillance with appropriate population-based estimates.
Period
16 Sept 2021
Event title
International Conference of Prevention and Infection Control